SEC Company Response from Atara Biotherapeutics, Inc. (ATRA) (CIK 0001604464) (ATRA) — Jul 7, 2015
Atara Biotherapeutics, Inc. (ATRA) (CIK 0001604464)
Date: July 7, 2015 · CIK: 0001604464 · Accession: 0001193125-15-246944
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-205347
Letter
Underwriters' Acceleration Request
Goldman, Sachs & Co.
200 West Street
New York, New York 10282
Citigroup Global Markets Inc.
388 Greenwich Street
New York, New York 10013
July 7, 2015
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn:
Jeffrey P. Riedler
Dan Greenspan
Scot Foley
Re:
Atara Biotherapeutics, Inc.
Registration Statement on Form S-1
Registration File No. 333-205347
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several Underwriters, hereby join in the request of Atara Biotherapeutics, Inc. (the “Company”) for acceleration of the effective date of the above-named Registration Statement so that it becomes effective at 4:30 PM Eastern Time on July 9, 2015, or as soon thereafter as practicable or at such other time as the Company or its outside counsel, Cooley LLP, request by telephone that such Registration Statement be declared effective.
Pursuant to Rule 460 under the Act, please be advised that there will be distributed to each Underwriter or dealer, who is reasonably anticipated to participate in the distribution of the security, as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
We, the undersigned, as representatives of the several Underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Very truly yours,
GOLDMAN, SACHS & CO.
Show Raw Text
CORRESP 1 filename1.htm Underwriters' Acceleration Request Goldman, Sachs & Co. 200 West Street New York, New York 10282 Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 July 7, 2015 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jeffrey P. Riedler Dan Greenspan Scot Foley Re: Atara Biotherapeutics, Inc. Registration Statement on Form S-1 Registration File No. 333-205347 Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several Underwriters, hereby join in the request of Atara Biotherapeutics, Inc. (the “Company”) for acceleration of the effective date of the above-named Registration Statement so that it becomes effective at 4:30 PM Eastern Time on July 9, 2015, or as soon thereafter as practicable or at such other time as the Company or its outside counsel, Cooley LLP, request by telephone that such Registration Statement be declared effective. Pursuant to Rule 460 under the Act, please be advised that there will be distributed to each Underwriter or dealer, who is reasonably anticipated to participate in the distribution of the security, as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus. We, the undersigned, as representatives of the several Underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. Very truly yours, GOLDMAN, SACHS & CO. CITIGROUP GLOBAL MARKETS INC. Acting severally on behalf of themselves and the several Underwriters By: GOLDMAN, SACHS & CO. By: /s/ Richard Cohn Name: Richard Cohn Title: Managing Director By: CITIGROUP GLOBAL MARKETS INC. By: /s/ Jennifer Jarrett Name: Jennifer Jarrett Title: MD [Signature Page to Underwriters’ Acceleration Request]